Compare CHCT & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | KMDA |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.6M | 385.3M |
| IPO Year | 2015 | N/A |
| Metric | CHCT | KMDA |
|---|---|---|
| Price | $15.26 | $7.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.00 | $13.00 |
| AVG Volume (30 Days) | ★ 323.0K | 71.8K |
| Earning Date | 10-28-2025 | 11-10-2025 |
| Dividend Yield | ★ 12.43% | 2.83% |
| EPS Growth | N/A | ★ 30.41 |
| EPS | N/A | ★ 0.35 |
| Revenue | $119,547,000.00 | ★ $174,787,000.00 |
| Revenue This Year | $6.97 | $14.90 |
| Revenue Next Year | $5.98 | $9.91 |
| P/E Ratio | ★ N/A | $20.04 |
| Revenue Growth | 3.40 | ★ 10.36 |
| 52 Week Low | $13.23 | $5.54 |
| 52 Week High | $20.87 | $9.16 |
| Indicator | CHCT | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 56.00 |
| Support Level | $15.18 | $6.70 |
| Resistance Level | $15.91 | $6.83 |
| Average True Range (ATR) | 0.45 | 0.15 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 56.77 | 72.42 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.